ライフサイエンスコーパス: fluorine-18

1 The most recent of these are labeled with fluorine-18.

2 olabeling with the positron-emitting isotope fluorine-18.

3 .83 nM) were selected for radiolabeling with fluorine-18.

4 with a positron-emitter, either carbon-11 or fluorine-18.

5 ssion tomographic (PET) radiopharmaceutical, fluorine 18 ((18)F) 2-fl uoropropionyl labeled PEGylated

6 tudy, a public NSCLC data set that contained fluorine 18 ((18)F) fluoro-2-deoxyglucose positron emiss

7 malignant brain lesions can be depicted with fluorine 18 ((18)F) fluorocholine positron emission tomo

8 mals were then injected with (99m)Tc ECDG or fluorine 18 ((18)F) fluorodeoxyglucose (FDG) (0.037-0.07

9 s) were compared with those of animals given fluorine 18 ((18)F) fluorodeoxyglucose (FDG) (n = 15, al

10 Purpose To compare fluorine 18 ((18)F) fluorodeoxyglucose (FDG) combined po

11 cyte-M-CSF (GM-CSF) and its implications for fluorine 18 ((18)F) fluorodeoxyglucose (FDG) imaging of

12 sessment of tissue-specific insulin-mediated fluorine 18 ((18)F) fluorodeoxyglucose (FDG) influx rate

13 th tumors who underwent clinically warranted fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT foll

14 onents of glucose metabolism, exemplified by fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

15 Purpose To assess whether dynamic fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

16 e the performance characteristics of interim fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

17 Computed tomography (CT), fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

18 (CT) of the chest, abdomen, and pelvis; and fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

19 that positron emission tomography (PET) with fluorine 18 ((18)F) fluorthanatrace (FTT) depicts activa

20 d finding that was further investigated with fluorine 18 ((18)F) flurodeoxyglucose (FDG) positron emi

21 identify quantitative imaging biomarkers at fluorine 18 ((18)F) positron emission tomography (PET) f

22 Molecules labeled with fluorine-18 ((18)F) are used in positron emission tomogr

23 Radiolabeling with fluorine-18 ((18)F) facilitated production of 2-(5,7-die

24 Among the beta(+)-emitting radionuclides, fluorine-18 ((18)F) is the isotope of choice for PET, an

25 The unnatural isotope fluorine-18 ((18)F) is used as a positron emitter in mol

26 An optimized procedure for preparing fluorine-18 ((18)F)-labeled peptides by the copper-catal

27 usefulness of fluorodesoxyglucose marked by fluorine-18 ((18)F-FDG) positron emission tomography (PE

28 Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron em

29 chest wall, and mediastinum were filled with fluorine-18 activities based on the average radionuclide

30 tsburgh Compound-B, the 110 min half-life of fluorine-18 allows for wider utilization in research and

31 thesis, and biological characterization of a fluorine-18 analog of dasatinib, a multitargeted kinase

32 ty were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron e

33 The fluorine-18 analogue was prepared via nucleophilic subst

34 imaging (positron emission tomography (PET)/fluorine-18) and treatment (targeted radionuclide therap

35 nd successfully radiolabeled with carbon-11, fluorine-18, and gallium-68.

36 Two of them were radiolabeled with fluorine-18, and their biodistribution was investigated

37 These compounds were radiolabeled with fluorine-18, and their biological properties were evalua

38 Molecules labeled with fluorine-18 are used as radiotracers for positron emissi

39 olecules labelled with the unnatural isotope fluorine-18 are used for positron emission tomography.

40 zinone derivatives labeled with carbon-11 or fluorine-18 as PDE5-specific PET tracers.

41 Fluorine-18-BPA-Fr PET is capable of providing in vivo B

42 acid (N-MeFAMP), have been radiolabeled with fluorine-18, characterized in amino acid uptake assays,

43 We evaluated the ability of fluorine-18 deoxyglucose positron emission tomography (F

44 Positron emission tomography with fluorine-18-deoxyglucose (FDG-PET) detects active lympho

45 Fluorine-18-FDG was administered to 18 Parkinson's disea

46 nts analysis (PCA) was applied to dynamic 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emis

47 e introduced on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emis

48 obtained after administration of 2-deoxy-2-[fluorine-18]fluoro-D-glucose in 39 patients with probabl

49 ith micro-PET by using the radiotracer 9-(4-[fluorine 18]-fluoro-3-hydroxymethylbutyl)-guanine (FHBG)

50 PET imaging of malignant tumors with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) as a tracer

51 The utility of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission

52 analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is

53 lculation of the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in tumor from small

54 PET with the labeled glucose analogue fluorine 18 fluorodeoxyglucose (FDG) is a relatively rec

55 lly suspected underwent clinically indicated fluorine 18 fluorodeoxyglucose (FDG) PET/CT and, immedia

56 he correlation between metabolic activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission t

57 ively compare the sensitivity of a dedicated fluorine 18 fluorodeoxyglucose (FDG) positron emission t

58 luate the positive predictive value (PPV) of fluorine 18 fluorodeoxyglucose (FDG) positron emission t

59 aging technique in body imaging is currently fluorine 18 fluorodeoxyglucose (FDG) positron emission t

60 Purpose To assess the diagnostic accuracy of fluorine 18 fluorodeoxyglucose (FDG) positron emission t

61 It has been reported that fluorine 18 fluorodeoxyglucose (FDG) positron emission t

62 he established patterns of hypometabolism on fluorine 18 fluorodeoxyglucose (FDG) positron emission t

63 trinsic contrast of melanin in comparison to fluorine 18 fluorodeoxyglucose (FDG) positron emission t

64 cal-pathologic nodal status with use of four fluorine 18 fluorodeoxyglucose (FDG) positron emission t

65 baseline magnetic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose (FDG) positron emission t

66 Fluorine 18 fluorodeoxyglucose (FDG) positron emission t

67 ss significant (P < .05) differences between fluorine 18 fluorodeoxyglucose (FDG) uptake of benign le

68 Fluorine 18 fluorodeoxyglucose (FDG) was mixed with diff

69 acilitate future direct correlations between fluorine 18 fluorodeoxyglucose (FDG)-avid colonic lesion

70 ts suspected of having abdominal or thoracic fluorine 18 fluorodeoxyglucose (FDG)-positive lesions un

71 and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG).

72 phic (CT) and (18)F-fluorodeoxyglucose ( FDG fluorine 18 fluorodeoxyglucose ) PET/CT examinations wer

73 Histograms of administered activity for fluorine 18 fluorodeoxyglucose and iodine 131 sodium iod

74 aging, and positron emission tomography with fluorine 18 fluorodeoxyglucose and novel tracers.

75 ermined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumo

76 olving a labeled dose of 370 MBq (10 mCi) of fluorine 18 fluorodeoxyglucose is estimated to involve a

77 nt contrast material-enhanced MR imaging and fluorine 18 fluorodeoxyglucose PEM in randomized order;

78 y (PET) and coregistered computed tomography/fluorine 18 fluorodeoxyglucose PET are used primarily in

79 rials and Methods Between 2010 and 2013, 219 fluorine 18 fluorodeoxyglucose PET examinations were per

80 etail methods for controlling the quality of fluorine 18 fluorodeoxyglucose PET imaging conditions to

81 l of 30 lesions were evaluated at (18)F- FDG fluorine 18 fluorodeoxyglucose PET/CT and (18)F- FPPRGD2

82 trointestinal malignancies underwent two FDG fluorine 18 fluorodeoxyglucose PET/CT examinations withi

83 Two hundred eighty-two fluorine 18 fluorodeoxyglucose PET/CT studies in 75 pedi

84 background is recommended in multicenter FDG fluorine 18 fluorodeoxyglucose PET/CT studies on the bas

85 ndmark finding relied on the use of clinical fluorine 18 fluorodeoxyglucose positron emission tomogra

86 Fluorine 18 fluorodeoxyglucose positron emission tomogra

87 es after injection, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximu

88 2.3) at 60 minutes, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximu

89 patients (20.7%) with adequate follow-up had fluorine 18 fluorodeoxyglucose-avid IMLN, with a median

90 CT scans is feasible and may be helpful when fluorine 18 fluorodeoxyglucose-avid masses that are not

91 ough positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ((18)F-FDG) has a major i

92 al (IB) routes and imaged sequentially using fluorine-18 fluorodeoxyglucose ((18)FDG) uptake as a non

93 y (PET) using nitrogen-13 (N-13) ammonia and fluorine-18 fluorodeoxyglucose (FDG) for imaging of perf

94 pectively investigated the value of PET with fluorine-18 fluorodeoxyglucose (FDG) for preoperative ch

95 hat positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may be useful for d

96 , and two underwent gallium scintigraphy and fluorine-18 fluorodeoxyglucose (FDG) positron emission t

97 a marker for tissue viability with regional fluorine-18 fluorodeoxyglucose (FDG) uptake in patients

98 There seems to be emerging roles for fluorine-18 fluorodeoxyglucose (FDG)-PET, laparoscopic s

99 The prognostic utility of midtreatment fluorine-18 fluorodeoxyglucose positron emission tomogra

100 Fluorine-18 fluorodeoxyglucose positron emission tomogra

101 Functional metabolic imaging through fluorine-18 fluorodeoxyglucose positron emission tomogra

102 erapy with both computed tomography (CT) and fluorine-18 fluorodeoxyglucose positron emission tomogra

103 d 20 nonsmoking control subjects underwent 2 fluorine 18-fluorodeoxyglucose positron emission tomogra

104 We visually compared fluorine-18-fluorodeoxyglucose (FDG)-PET images to radio

105 rves (TACs) from mouse PET studies done with fluorine-18-fluorodeoxyglucose (FDG).

106 Fluorine-18-fluorodeoxyglucose detected unsuspected meta

107 Fluorine-18-fluorodeoxyglucose imaging was more accurate

108 magnetic resonance imaging and angiography, fluorine-18-fluorodeoxyglucose positron emission tomogra

109 s, positron emission tomography imaging with fluorine-18-fluorodeoxyglucose, and cardiac magnetic res

110 ing positron emission tomography (PET) with [fluorine-18]fluorodopa (F18-DOPA), we compared the integ

111 sthetic group was synthesized to incorporate fluorine-18 for PET imaging.

112 Fluorine-18-FPCIT showed a striatum-to-occipital ratio (

113 Fluorine-18-FPH appears to be a suitable tracer to study

114 Fluorine-18-FPH labels nAChR in vivo in the mouse brain.

115 Fluorine-18-FPH was administered intravenously to mice,

116 Fluorine-18-FTHA EF paralleled the changes in beta-oxida

117 lled modular build-up approach), introducing fluorine-18 in a fast and efficient manner in a building

118 by late-stage radiofluorination, introducing fluorine-18 in the last step of the synthesis, or by a b

119 for SULT1E1 can be labeled with carbon-11 or fluorine-18, in vivo assays of SULT1E1 functional activi

120 Fluorine-18 is the most frequently used radioisotope in

121 Fluorine-18 is the most widely used radioisotope for PET

122 dopamine synthesis capacity was measured by fluorine-18-l-dihydroxyphenylalanine (F-18-FDOPA) positr

123 Exposures: Imaging with fluorine 18-labeled AV-1451 ([18F]AV-1451) (formerly kno

124 orylated tau pathologic findings measured by fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emis

125 emission tomography imaging with radiotracer fluorine 18-labeled florbetapir.

126 Inflammatory cells have avidity for fluorine 18-labeled fluorodeoxyglucose ((18)F-FDG), and

127 Fluorine 18-labeled fluoromisonidazole ([18F]FMISO), a P

128 ositron emission tomography with radioligand fluorine 18-labeled setoperone as the tracer.

129 Fluorine-18-labeled 2 beta-carbomethoxy-3 beta-(4-chloro

130 x (10(6) p/s/cm(2)/sr)] but similar level of fluorine-18-labeled 2'-fluoro-2'-deoxyarabinofuranosyl-5

131 ic positron emission tomography imaging with fluorine-18-labeled 2-fluoro-2-deoxyglucose ((18)FDG) li

132 1, and glycolytic genes, hk1 and pdk1, lung fluorine-18-labeled 2-fluoro-2-deoxyglucose ligand uptak

133 her accumulation (P < 0.05) of 18F-FEAU than fluorine-18-labeled 9-(4-fluoro-3-hydroxymethylbutyl)gua

134 Existing fluorine-18-labeled amino acid-based radiotracers predom

135 itron emission tomography (PET) imaging with fluorine-18-labeled androgens.

136 Although inflammation can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission

137 based labeling method was used to synthesize fluorine-18-labeled insulin specifically B(1)-(4-[(18)F]

138 In the search for an optimal fluorine-18-labeled positron emission tomography (PET) r

139 cross-linking noninvasively, we developed a fluorine-18-labeled positron emission tomography agent (

140 It is likely that more than one fluorine-18-labeled tracer will come into common use.

141 Prior to fluorine-18 labeling, the nonradioactive fluoro derivati

142 overview of the synthesis and application of fluorine-18 labelled building blocks since 2010.

143 lucose homeostasis was studied in mice using fluorine-18 labelled glucose molecular imaging probes an

144 or selection of a synthetic approach for new fluorine-18 labelled PET tracers.

145 Further advances are being made with other fluorine-18-labelled and generator-based PET tracers, th

146 After injection with fluorine-18-labelled fluorodeoxyglucose, patients underw

147 tumour and normal-tissue pharmacokinetics of fluorine-18-labelled fluorouracil.

148 eatures but uncertain clinical diagnosis had fluorine-18-labelled-fluorodeoxyglucose-PET at The Feins

149 Fluorine-18-PFBG is specifically accumulated by sympathe

150 Fluorine-18-PFBG was administered to working rat hearts

151 temetamol injection labeled with radioactive fluorine 18 positron emission tomography imaging for bra

152 (PTC) (e.g. kryptofix 2.2.2) associated with fluorine-18 preparation has been found to be detrimental

153 l molecules, peptides, and proteins with the fluorine-18 prosthetic [(18)F]4-fluorophenylboronic acid

154 The new procedures are effective for fluorine-18 radiochemistry and, as proof of concept, hav

155 challenging to synthesize using traditional fluorine-18 radiochemistry.

156 series of candidates, radiolabeled them with fluorine-18 radioisotope, and determined their physicoch

157 4), magnetic resonance imaging (n = 3), and fluorine-18 sodium fluoride positron emission tomography

158 PET and SPECT, with fluorine-18 sodium fluoride, were performed sequentially

159 Compound 9 was labeled with fluorine-18 (t(1/2) = 109.7 min) in high specific activi

160 ter, either carbon-11 (t(1/2) = 20.4 min) or fluorine-18 (t(1/2) = 109.7 min), and included (i) repla

161 Fluorine-18 (t(1/2)=109.7 min) is the most commonly used

162 Compound 3 was labeled with fluorine-18 (t1/2 = 109.7 min) in high radiochemical yie

163 ctively targeting the ghrelin receptor using fluorine-18 tagged entities would allow localization and

164 f thioethers to be labeled with carbon-11 or fluorine-18 through S-alkylation reactions.

165 -1 (sigma1) receptors were radiolabeled with fluorine-18 via displacement of the corresponding mesyla

166 temetamol injection labeled with radioactive fluorine 18 (Vizamyl; GE Healthcare) administration foll

167 temetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specif

168 Incorporation of fluorine-18 was achieved by nucleophilic displacement of

169 Fluorine-18 was introduced into 2 beta-carbomethoxy-3 be

170 Nanoparticles containing fluorine-18 were prepared from block copolymers made by